Literature DB >> 32155272

Cardiomyopathy in Thalassemia: Quick Review from Cellular Aspects to Diagnosis and Current Treatments.

Majid Ghanavat1, Habib Haybar2, Seyed Mohammad Sadegh Pezeshki3, Mohammad Shahjahani3, Hosein Jodat3, Milad Elyasi3, Najmaldin Saki1,3.   

Abstract

BACKGROUND: Cardiomyopathic manifestations induced by continuous blood transfusion are the leading cause of death among patients with thalassemia major (TM). Despite introduction of chelation therapy, heart failure after cardiomyopathic manifestations is still a major threat to patients.
METHODS: We performed a search of relevant English-language literature, retrieving publications from the PubMed database and the Google Scholar search engine (2005-2018). We used "thalassemia major", "cardiomyopathy", "iron overload", "cardiac magnetic resonance T2" "chelation therapy", and "iron burden" as keywords.
RESULTS: The results of the studies we found suggest that cardiac hepcidin is a major regulator of iron homeostasis in cardiac tissue. Unlike previous assumptions, the heart appears to have a limited regeneration capability, originating from a small population of hypoxic cardiomyocytes.
CONCLUSIONS: Oxygen levels determine cardiomyocyte gene-expression patterns. Upregulation of cardiac hepcidin in hypoxia preserves cardiomyocytes from forming out of reactive oxygen species catalyzed by free cellular iron in cardiomyocytes. Using the limited regeneration capacity of cardiac cells and gaining further understanding of the cellular aspects of cardiomyopathic manifestations may help health care professionals to develop new therapeutic strategies. © American Society for Clinical Pathology 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cardiac magnetic resonance T2; cardiomyopathy; chelation therapy; iron burden; iron overload; thalassemia major

Mesh:

Year:  2020        PMID: 32155272     DOI: 10.1093/labmed/lmz052

Source DB:  PubMed          Journal:  Lab Med        ISSN: 0007-5027


  3 in total

Review 1.  Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.

Authors:  Hadi Darvishi-Khezri; Hossein Karami
Journal:  Adv Ther       Date:  2021-03-04       Impact factor: 3.845

2.  Early Detection of Iron Overload Cardiomyopathy in Transfusion Dependent Thalassemia Patients in Sulaimaniyah City, Iraq.

Authors:  Rana Adnan Ahmed; Aso Faeq Salih; Shirwan Hamasalih Omer; Heshu Sulaiman Rahman; Luqman Khalid Rasool
Journal:  Ther Clin Risk Manag       Date:  2022-03-22       Impact factor: 2.423

Review 3.  Ferroptosis in Cardiovascular Diseases: Current Status, Challenges, and Future Perspectives.

Authors:  Yi Guo; Chanjun Lu; Ke Hu; Chuanqi Cai; Weici Wang
Journal:  Biomolecules       Date:  2022-03-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.